ClinicalTrials.gg
Active, not recruitingNCT03455725CardiAMP-CMIUpdated Jan 6, 2026

CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial

An interventional study of CardiAMP Cell Therapy System and Sham Treatment in Refractory Angina and Chronic Myocardial Ischemia, sponsored by BioCardia, Inc.. Active, not recruiting at 2 sites in United States. Open to participants aged 21 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-01-06.

Sponsored by BioCardia, Inc. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
343
Allocation
Randomized
Ages
21 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 113 studies in Angina Pectoris with a site in United States — 13 open to participants now, 17 under way, 2 of them phase 3. Angina Pectoris · United States.

Planned enrollment
18th of 73
343 · median 124
Started
2021
with 2 others
No phase
30 of 113
6 open now
Primary completion
2025-02
later than 0 of 16 live
Registered
86th of 113
by date

Among the 113 studies in Angina Pectoris with a site in United States, this one is the 18th largest by planned enrollment of the 73 interventional ones that give a count, is one of 3 that started in 2021, is one of 30 with no phase, reaches primary completion later than 0 of the 16 other live ones, and was the 86th registered.

Angina Pectoris

454 studies on the registry are indexed under Angina Pectoris; 67 are open to participants now.

Browse Angina Pectoris studies →

Open to participants now

13 of the 113 studies in Angina Pectoris with a site in United States are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 46 Angina Pectoris studies recruiting now, 34 (74%) set no upper age limit and 1 (2%) stops at 75 or younger; 3 take children under 18; 5 take healthy volunteers.

This study: 21 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies in Angina Pectoris with a site in United States, or all of them as a file.
02

Study summary

Prospective, multi-center, 2:1 randomized (Treatment : Sham Control), sham-controlled, double-blinded trial to compare treatment using the CardiAMP cell therapy system to sham treatment

Treatment Group:

Subjects treated with aBMC using the CardiAMP cell therapy system

Sham Control Group:

Subjects treated with a Sham Treatment (no introduction of the Helix transendocardial delivery catheter, no administration of aBMC)

03

Conditions studied

  • Refractory Angina
  • Chronic Myocardial Ischemia

Browse trials for

Keywords

  • Cardiovascular Stem Cell Therapy
  • Bone Marrow Mononuclear Stem Cells
  • Intramyocardial Injection
04

Who can participate

Ages eligible
21 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female 21 to 80 years of age
  2. Canadian Cardiovascular Society (CCS) class III or IV chronic angina.
  3. Lack of control of angina symptoms despite maximum tolerated doses of anti-angina drugs.
  4. Evidence of inducible myocardial ischemia on baseline stress testing
  5. Obstructive coronary disease unsuitable for conventional revascularization
  6. Experience angina episodes at a minimum of 7 angina episodes per week (during a 4-week screening period).
  7. Able to complete an exercise tolerance test on the treadmill
  8. of greater than or equal to 40% as measured by echocardiography.
  9. Qualification of a pre-procedure screening of bone-marrow aspiration

Exclusion criteria

Exclusion Criteria

Other cardiac or vascular system or other health-related criteria which may be seen in a patient's history and physical examination.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
343 participants (estimated)

Study arms

  • Active comparator
    CardiAMP cell therapy system

    Roll-in phase: Up to 10 subjects with refractory chronic myocardial ischemia CCS class III-IV will be treated in an unblinded, uncontrolled roll-in phase. In the subsequent randomized phase: Up to 333 subjects with refractory chronic myocardial ischemia CCS class III-IV will be randomized. Up to 222 Subjects will be randomized to treatment with the CardiAMP cell therapy system.

    Device: CardiAMP Cell Therapy System

  • Sham comparator
    Sham procedure control

    Randomized phase: Up to 333 subjects with refractory chronic myocardial ischemia CCS class III-IV will be randomized. Up to 111 subjects will be treated with a Sham Treatment (no introduction of trans endocardial delivery catheter and no administration of autologous cells)

    Other: Sham Treatment

Interventions

  • DeviceCardiAMP Cell Therapy System

    The CardiAMP Cell Therapy system consists of the CardiAMP Potency Assay, the Helix/Morph intramyocardial delivery catheter system, and the CardiAMP Cell Separator. The system allows the investigator to identify patients with a high chance to respond to im autologous stem cell therapy (using the CardiAMP Cell Potency Assay), to isolate the stem cells from a bone marrow harvest at the point of care (using the CardiAMP CS system), and to percutaneously inject the autologous cells into the myocardium using the Helix/Morph delivery catheters.

  • OtherSham Treatment

    Patients will receive sham bone marrow procedure and a ventriculogram. A scripted sham percutaneous procedure will be performed

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Total Exercise Time on the treadmill using the Modified Bruce Protocol

    A superiority analysis with regards to change from Baseline in Total Exercise Time at the 6 months follow-up visit (using a Modified Bruce Protocol).

    Time frame: Baseline and 6 months visit

Secondary outcomes

  1. Safety: overall survival at 6 months follow-up

    A non-inferiority analysis of overall survival at 6-months will be made comparing the Treatment group to the Sham Control group using a non-inferiority margin of 10%.

    Time frame: at 6 months follow-up

  2. Safety: Total Major adverse cardiac events (MACE) at 6 months follow-up

    A non-inferiority analysis with regard to Total Major Adverse Cardiac Events (MACE: defined as death, cardiac hospitalization, non-fatal myocardial infarction and stroke) at 12 month follow-up, as adjudicated by an independent clinical endpoint classification (CEC) committee with 10% margin.

    Time frame: from randomisation to 6 months follow-up

  3. Efficacy: Change from baseline in Total Exercise Time at 6 months follow-up

    Superiority analysis with regards to change from baseline in Total Exercise Time on Exercise Tolerance Test (ETT) at 6 Month Follow-up Visit. Baseline (BL) is the average of (at least) two total exercise times measured during the screening period.

    Time frame: Baseline and at 6 months follow-up

  4. Efficacy: Change of angina frequency (per week) at 12 months follow-up

    Superiority analysis with regards to change in angina frequency (episodes per week) at 12 month follow-up Visit versus baseline angina frequency (per week). Participants self-reported angina episodes utilizing an electronic diary for 4 weeks at baseline (screening period) and in the 4 weeks before the 12-month follow-up visits.

    Time frame: Baseline and at 12 months follow-up

  5. Efficacy: Change of Angina Frequency (per week) at 6 months follow-up

    Superiority analysis with regards to change in angina frequency at 6 month follow-up visit versus baseline (expressed as angina frequency per week). Participants self-reported angina episodes utilizing an electronic diary for 4 weeks at baseline and in the 4 weeks before the 6-month follow-up visits.

    Time frame: Baseline and at 6 months follow-up

  6. Safety: Total Major adverse cardiac events (MACE) at 12 months follow-up

    Superiority analysis with regards to incidence of MACE from Randomization until the end of the 24 month follow-up period

    Time frame: From randomisation to 12 month follow-up

  7. Efficacy: Percentage of patients with at least 1 Serious Adverse Event (SAE)

    Superiority analysis with regards to percentage of participants with at least one SAE. From randomization until the end of the 12 month follow-up period.

    Time frame: From randomization to 12 Months follow-up

07

Study locations

2 sites
08

References and documents

Related links

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2021 to primary completion in Feb 2025, 43 months.

Of 72 interventional studies with no phase under Angina Pectoris, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 64. This study's 43 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2018
First posted
Mar 7, 2018
StartActual
Jun 30, 2021
Primary completionActual
Feb 19, 2025
CompletionEst.
Dec 2027
Last update
Jan 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03455725
Lead sponsor
BioCardia, Inc.
Responsible party
Sponsor
First posted
Mar 7, 2018
Start date
Jun 30, 2021
Primary completion
Feb 19, 2025
Completion
Dec 2027 (estimated)
Last update
Jan 6, 2026

Study contacts

Amish Raval, MD
principal investigator · University of Wisconsin, Madison

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion